Leukocyte telomere shortening in Huntington's disease.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 23 07 2018
revised: 26 10 2018
accepted: 26 10 2018
pubmed: 6 11 2018
medline: 23 7 2019
entrez: 6 11 2018
Statut: ppublish

Résumé

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an expanded CAG repeat. Though symptom onset commonly occurs at midlife and inversely correlates with the CAG repeat expansion, age at clinical onset and progression rate are variable. In the present study we investigated the relationship between leukocyte telomere length (LTL) and HD development. LTL was measured by real-time PCR in manifest HD patients (HD, n = 62), pre-manifest HD patients (pre-HD, n = 38), and age-matched controls (n = 76). Significant LTL differences were observed between the three groups (p < .0001), with LTL values in the order: HD < pre-HD < controls. The relationship between LTL and age was different in the three groups. An inverse relationship between mean LTL and CAG repeat number was found in the pre-HD (p = .03). The overall data seem to indicate that after age 30 years, LT begins to shorten markedly in pre-HD patients according to CAG number and increasing age, up to the values observed in HD. This very suggestive picture allowed us to hypothesize that in pre-manifest HD, LTL could be a measure of time to clinical HD onset. The possible use of LTL as a reliable biomarker to track HD development and progression was evaluated and discussed.

Identifiants

pubmed: 30396032
pii: S0022-510X(18)30434-9
doi: 10.1016/j.jns.2018.10.024
pii:
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-29

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Daniela Scarabino (D)

CNR Institute of Molecular Biology and Pathology, c/o Department of Biology and Biotechnology, P.le Aldo Moro 5, 00185 Rome, Italy.

Liana Veneziano (L)

CNR Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy.

Martina Peconi (M)

CNR Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy; Department of Biology and Biotechnology, La Sapienza University, P.le Aldo Moro 5, 00185 Rome, Italy.

Marina Frontali (M)

CNR Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy.

Elide Mantuano (E)

CNR Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy.

Rosa Maria Corbo (RM)

CNR Institute of Molecular Biology and Pathology, c/o Department of Biology and Biotechnology, P.le Aldo Moro 5, 00185 Rome, Italy; Department of Biology and Biotechnology, La Sapienza University, P.le Aldo Moro 5, 00185 Rome, Italy. Electronic address: rosamaria.corbo@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH